Generated: October 20, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205437
, which is a drug marketed by Celgene Corp and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the OTEZLA profile page.
The generic ingredient in OTEZLA is apremilast. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.
Summary for NDA: 205437
|Formulation / Manufacturing:||see details|
Pharmacology for NDA: 205437
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Mar 21, 2014||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Mar 21, 2019
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Sep 23, 2017
|Regulatory Exclusivity Use:||TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY|
|Patent:||► Subscribe||Patent Expiration:||Oct 30, 2018||Product Flag?||Y||Substance Flag?||Y||Delist Request?|| |
|Patented Use:||USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4|
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.